Several pharmacological agents to prevent the progression of diabetic kidney disease（DKD） have been tested in patients with type 2 diabetes mellitus（T2 DM） in the past two decades. With the exception of renin-angiotensin system blockers that have shown a significant reduction in the progression of DKD in 2001, no other pharmacological agent tested in the past two decades have shown any clinically meaningful result. Recently, the sodium-glucose cotransporter-2 inhibitor（SGLT-2 i）, canagliflozin, has shown a significant reduction in the composite of hard renal and cardiovascular（CV） endpoints including progression of end-stage kidney disease in patients with DKD with T2 DM at the top of reninangiotensin system blocker use. Another SGLT-2 i, dapagliflozin, has also shown a significant reduction in the composite of renal and CV endpoints including death in patients with chronic kidney disease（CKD）, regardless of T2 DM status. Similar positive findings on renal outcomes were recently reported as a top-line result of the empagliflozin trial in patients with CKD regardless of T2 DM. However, the full results of this trial have not yet been published. While the use of older steroidal mineralocorticoid receptor antagonists（MRAs） such as spironolactone in DKD is associated with a significant reduction in albuminuria outcomes, a novel non-steroidal MRA finerenone has additionally shown a significant reduction in the composite of hard renal and CV endpoints in patients with DKD and T2 DM, with reasonably acceptable side effects.